Evidence map›Paper›PMID 38589699›Full record

ArticlePediatric nephrology (Berlin, Germany)2024

Outcome 10 years after Shiga toxin-producing E. coli (STEC)-associated hemolytic uremic syndrome: importance of long-term follow-up.

Alejandra Rosales, Sarah Kuppelwieser, Thomas Giner, Johannes Hofer, Magdalena Riedl Khursigara, Dorothea Orth-Höller, Wegene Borena, Gerard Cortina, Therese Jungraithmayr, Reinhard Würzner and 1 more

Abstract read
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Proteinuria in adolescence.Pediatric nephrology (Berlin, Germany) · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alejandra RosalesDepartment of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria. alejandra.rosales@i-med.ac.at.ORCID http://orcid.org/0000-0002-8819-5302
Sarah KuppelwieserDepartment of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria.
Thomas GinerDepartment of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria.
Johannes HoferResearch Institute for Developmental Medicine, Johannes Kepler University, Linz, Austria.
Magdalena Riedl KhursigaraDivision of Nephrology, The Hospital for Sick Children, Toronto, ON, Canada.
Dorothea Orth-HöllerInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Wegene BorenaInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
Gerard CortinaDepartment of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria.
Therese JungraithmayrDepartment of Pediatrics, Medical University of Innsbruck, Innsbruck, Austria.
Reinhard WürznerInstitute of Hygiene and Medical Microbiology, Medical University of Innsbruck, Innsbruck, Austria.
German-Austrian H. U. S.-Study Group

Funding

Bundesministerium für Bildung und Forschung 01K19905Oesterreichische Nationalbank 12771Oesterreichische Nationalbank 13655
6 · The paper itself

Abstract

backgroundHemolytic uremic syndrome (HUS) is an important cause of acute kidney injury in children. HUS is known as an acute disease followed by complete recovery, but patients may present with kidney abnormalities after long periods of time. This study evaluates the long-term outcome of Shiga toxin-producing Escherichia coli-associated HUS (STEC-HUS) in pediatric patients, 10 years after the acute phase of disease to identify risk factors for long-term sequelae.

methodsOver a 6-year period, 619 patients under 18 years of age with HUS (490 STEC-positive, 79%) were registered in Austria and Germany. Long-term follow-up data of 138 STEC-HUS-patients were available after 10 years for analysis.

resultsA total of 66% (n = 91, 95% CI 0.57-0.73) of patients fully recovered showing no sequelae after 10 years. An additional 34% (n = 47, 95% CI 0.27-0.43) presented either with decreased glomerular filtration rate (24%), proteinuria (23%), hypertension (17%), or neurological symptoms (3%). Thirty had sequelae 1 year after STEC-HUS, and the rest presented abnormalities unprecedented at the 2-year (n = 2), 3-year (n = 3), 5-year (n = 3), or 10-year (n = 9) follow-up. A total of 17 patients (36.2%) without kidney abnormalities at the 1-year follow-up presented with either proteinuria, hypertension, or decreased eGFR in subsequent follow-up visits. Patients needing extracorporeal treatments during the acute phase were at higher risk of presenting symptoms after 10 years (p < 0.05).

conclusionsPatients with STEC-HUS should undergo regular follow-up, for a minimum of 10 years following their index presentation, due to the risk of long-term sequelae of their disease. An initial critical illness, marked by need of kidney replacement therapy or plasma treatment may help predict poor long-term outcome.

Indexed as

Escherichia coli InfectionsHemolytic-Uremic SyndromeShiga-Toxigenic Escherichia coliAdolescentAustriaChildChild, PreschoolFemaleFollow-Up StudiesGermanyGlomerular Filtration RateHumansInfantMaleProteinuriaRisk FactorsEscherichia coliHemolytic uremic syndromeKidney replacement therapyOutcomeShiga toxin

Identifiers

PMID38589699
PMCPMC11199238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.